World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
23864
World Ranking
17518
National Ranking
1586

Anthony V. Moorman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anthony V. Moorman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 353 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anthony V. Moorman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony V. Moorman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anthony V. Moorman is affiliated with Newcastle University in the United Kingdom. Their research focuses primarily on Medicine, with significant contributions in the subfields of Public Health, Environmental and Occupational Health, Hematology, Pediatrics, Perinatology and Child Health, Oncology, and Molecular Biology.

The scientist's work centers on topics including Acute Lymphoblastic Leukemia research, Childhood Cancer Survivors' Quality of Life, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, CAR-T cell therapy research, Cancer Genomics and Diagnostics, and Chronic Lymphocytic Leukemia Research.

Recent papers authored or co-authored by Anthony V. Moorman include:

  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL, 2021, published in Blood
  • Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia, 2023, published in Leukemia
  • Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study, 2020, published in The Lancet Haematology
  • Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group, 2021, published in Leukemia
  • Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials, 2021, published in the European Journal of Cancer

Their frequent co-authors include:

  • Ajay Vora (36 publications)
  • Christine J. Harrison (26 publications)
  • Amir Enshaei (23 publications)
  • Adele K. Fielding (17 publications)
  • Amy A. Kirkwood (16 publications)

Anthony V. Moorman has published extensively in several key venues:

  • Blood (23 publications)
  • Leukemia (15 publications)
  • HemaSphere (6 publications)
  • Journal of Clinical Oncology (5 publications)
  • Blood Advances (5 publications)

Best Publications

  • Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

    David Grimwade;Robert K. Hills;Anthony V. Moorman;Helen Walker

  • Genetic variegation of clonal architecture and propagating cells in leukaemia

    Kristina Anderson;Christoph Lutz;Frederik W. van Delft;Caroline M. Bateman

  • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

    Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • Deregulated expression of cytokine receptor gene, CRLF2 , is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

    Lisa J. Russell;Melania Capasso;Inga Vater;Takashi Akasaka

  • Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

    Anthony V Moorman;Hannah M Ensor;Sue M Richards;Lucy Chilton

  • T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

    David I. Marks;Elisabeth M. Paietta;Anthony V. Moorman;Susan M. Richards

  • UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

    Adele K. Fielding;Jacob M. Rowe;Georgina Buck;Letizia Foroni

  • Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

    Chirstine J. Harrison;Robert Kerrin Hills;Anthony V. Moorman;David J. Grimwade

  • The genetic basis and cell of origin of mixed phenotype acute leukaemia

    Thomas B. Alexander;Thomas B. Alexander;Zhaohui Gu;Ilaria Iacobucci;Kirsten Dickerson

  • Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

    Catriona Parker;Rachel Waters;Carly Leighton;Carly Leighton;Jeremy Hancock

  • Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ECOG2993

    Adele K. Fielding;Jacob M. Rowe;Susan M. Richards;Georgina Buck

  • Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

    Ajay Vora;Nick Goulden;Chris Mitchell;Jeremy Hancock

  • Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia

    James M. Allan;Christopher P. Wild;Sara Rollinson;Eleanor V. Willett

  • RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

    David T. Bowen;Marion E. Frew;Robert Kerrin Hills;Rosemary E. Gale

  • PROGNOSTIC FACTOR ANALYSIS OF THE SURVIVAL OF ELDERLY PATIENTS WITH AML IN THE MRC AML11 AND LRF AML14 TRIALS

    Keith Wheatley;Cassandra l. Brookes;Andrew J. Howman;Anthony H. Goldstone

  • Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk

    Amy L. Sherborne;Fay J. Hosking;Rashmi B. Prasad;Rajiv Kumar

  • Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia

    Yilong Li;Claire Schwab;Sarra L. Ryan;Elli Papaemmanuil

  • Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

    Trudy D. Buitenkamp;Shai Izraeli;Martin Zimmermann;Erik Forestier

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

    A Moorman;C J Harrison;Buck Gan.;S M Richards

Frequent Co-Authors

Christine J. Harrison
Christine J. Harrison Newcastle University
Charles G. Mullighan
Charles G. Mullighan St. Jude Children's Research Hospital
Anthony H. Goldstone
Anthony H. Goldstone University College Hospital
Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
Martin Schrappe
Martin Schrappe Kiel University
Eve Roman
Eve Roman University of York
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
David I. Marks
David I. Marks University Hospitals Bristol NHS Foundation Trust
Alan Kenneth Burnett
Alan Kenneth Burnett University of Glasgow

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in a healthcare career or seeking to expand their medical qualifications in the USA, online nursing and advanced practice degrees provide flexible and accelerated options. Fast-track programs are highly sought after by working professionals aiming to quickly progress in their careers. For example, completing a 6 month lpn program can help individuals launch their nursing career in less than a year, saving both time and tuition.

Nurses with an MSN who want to advance further might consider the fastest msn to dnp program available online. These programs are designed for efficiency, allowing students to become doctorally prepared nurses in a shorter duration. For those who prefer a less research-intensive pathway, there are also online dnp programs without dissertation, which eliminate the need for a traditional lengthy dissertation and focus more on clinical skills and leadership.

Furthermore, mental health is a growing field in medical care. Qualified nurses can specialize further with online psych np programs, gaining expertise to support patients with psychiatric needs. These diverse online degree options offer efficient and accessible routes to rewarding healthcare careers.

Best Scientists Citing Anthony V. Moorman

Trending Scientists

Recently Published Articles